Benitec Biopharma's 15min chart triggered KDJ Golden Cross, Bullish Marubozu Signal
ByAinvest
Thursday, Sep 11, 2025 1:19 pm ET2min read
ALNY--
The KDJ Golden Cross, generated by the KDJ indicator, occurs when the K line crosses above the D line, often seen as a bullish signal indicating a potential shift in the stock's momentum towards the upside [1]. The Bullish Marubozu, characterized by a long body with no shadows above or below, suggests that the stock is being driven by strong buying pressure [1].
While these technical indicators provide valuable insights into the potential direction of Benitec Biopharma's stock price, investors should consider them in conjunction with fundamental analysis and broader market conditions. Benitec Biopharma has demonstrated strong financial health and shareholder commitment through its recent dividend hike and consistent earnings growth [2].
Several notable companies have seen updates to their analyst ratings and price targets, reflecting the evolving opinions of financial experts. For example, Alnylam Pharma (ALNY) received a "Buy" rating from Jefferies with a price target of $384.00 [1]. Chime Financial (CHYM) was initiated with an "Overweight" rating by multiple firms, including Morgan Stanley and Barclays, with targets ranging from $39.00 to $40.00 [1]. CryoPort (CYRX) was rated "Buy" by BTIG Research with a price target of $10.00 [1]. Datadog (DDOG) had its price target raised from $150.00 to $175.00 by Bank of America, reiterating a "Buy" rating [1]. Energy Transfer (ET) was initiated with a "Buy" rating by TD Cowen with a price target of $22.00 [1]. Grab (GRAB) was rated "Buy" by Jefferies with a price target of $5.70, indicating a 20.94% upside [1]. Home Depot (HD) was rated "Buy" by TD Cowen with a price target of $470.00 [1]. Intuit (INTU) was rated "Buy" by Morgan Stanley with a price target of $900.00 [1]. JPMorgan Chase & Co. (JPM) had a $298.00 target set by Evercore ISI with an "Outperform" rating [1]. Kinder Morgan (KMI) was initiated with a "Buy" rating by TD Cowen [1]. Lam Research (LRCX) had its "Buy" rating reiterated by Citigroup [1]. MACOM Technology Solutions (MTSI) had its target raised from $136.00 to $154.00 by Truist Financial, maintaining a "Buy" rating [1]. Monopar Therapeutics (MNPR) was initiated with an "Overweight" rating by Cantor Fitzgerald and a target of $74.00 [1]. Norwegian Cruise Line (NCLH) received a "Buy" rating from Jefferies with a price target of $29.00 [1]. Oracle (ORCL) received a "Buy" rating from UBS with a $250.00 target [1]. Oportun Financial (OPRT) was rated "Buy" at B. Riley Financial with an $11.00 price target [1]. Ovintiv (OVV) was rated "Buy" at Barclays Capital with a price target of $55.00 [1]. Phibro Animal Health (PAHC) was upgraded at JPMorgan Chase from Neutral to Overweight, with the price target raised from $25.00 to $35.00 [1]. Progressive (PGR) was downgraded by Morgan Stanley from Overweight to Equal Weight, with a price target of $290.00 [1]. Pulse Biosciences (PLSE) was initiated by Oppenheimer with an "Outperform" rating and a $22.00 price target [1]. PTC (PTC) had its Overweight rating reiterated by KeyCorp Bank [1]. Rockwell Automation (ROK) was initiated by CICC Research with a "Buy" rating and a price target of $320.00 [1].
[1] https://www.ainvest.com/news/business-15min-chart-triggers-bollinger-bands-narrowing-bearish-marubozu-pattern-2508/
[2] https://www.ainvest.com/news/trico-bancshares-9-1-dividend-hike-testament-financial-resilience-shareholder-commitment-2508/
BAC--
BCS--
BINI--
BNTC--
As per the 15-minute chart for Benitec Biopharma, a Golden Cross of the KDJ indicator has been triggered, coupled with a Bullish Marubozu at 09/11/2025 13:15. This suggests that the momentum of the stock price is shifting towards an upward trajectory, with a potential for further growth. The buyers are in control of the market, and it is likely that the bullish momentum will continue.
According to the latest 15-minute chart analysis of Benitec Biopharma (BNTC), a significant technical indicator, the KDJ Golden Cross, has been triggered. This development, coupled with the presence of a Bullish Marubozu observed on September 11, 2025, at 13:15, signifies a shift in the momentum of the stock price towards the upside [1]. These indicators suggest a potential for further price appreciation, as buyers are in control of the market.The KDJ Golden Cross, generated by the KDJ indicator, occurs when the K line crosses above the D line, often seen as a bullish signal indicating a potential shift in the stock's momentum towards the upside [1]. The Bullish Marubozu, characterized by a long body with no shadows above or below, suggests that the stock is being driven by strong buying pressure [1].
While these technical indicators provide valuable insights into the potential direction of Benitec Biopharma's stock price, investors should consider them in conjunction with fundamental analysis and broader market conditions. Benitec Biopharma has demonstrated strong financial health and shareholder commitment through its recent dividend hike and consistent earnings growth [2].
Several notable companies have seen updates to their analyst ratings and price targets, reflecting the evolving opinions of financial experts. For example, Alnylam Pharma (ALNY) received a "Buy" rating from Jefferies with a price target of $384.00 [1]. Chime Financial (CHYM) was initiated with an "Overweight" rating by multiple firms, including Morgan Stanley and Barclays, with targets ranging from $39.00 to $40.00 [1]. CryoPort (CYRX) was rated "Buy" by BTIG Research with a price target of $10.00 [1]. Datadog (DDOG) had its price target raised from $150.00 to $175.00 by Bank of America, reiterating a "Buy" rating [1]. Energy Transfer (ET) was initiated with a "Buy" rating by TD Cowen with a price target of $22.00 [1]. Grab (GRAB) was rated "Buy" by Jefferies with a price target of $5.70, indicating a 20.94% upside [1]. Home Depot (HD) was rated "Buy" by TD Cowen with a price target of $470.00 [1]. Intuit (INTU) was rated "Buy" by Morgan Stanley with a price target of $900.00 [1]. JPMorgan Chase & Co. (JPM) had a $298.00 target set by Evercore ISI with an "Outperform" rating [1]. Kinder Morgan (KMI) was initiated with a "Buy" rating by TD Cowen [1]. Lam Research (LRCX) had its "Buy" rating reiterated by Citigroup [1]. MACOM Technology Solutions (MTSI) had its target raised from $136.00 to $154.00 by Truist Financial, maintaining a "Buy" rating [1]. Monopar Therapeutics (MNPR) was initiated with an "Overweight" rating by Cantor Fitzgerald and a target of $74.00 [1]. Norwegian Cruise Line (NCLH) received a "Buy" rating from Jefferies with a price target of $29.00 [1]. Oracle (ORCL) received a "Buy" rating from UBS with a $250.00 target [1]. Oportun Financial (OPRT) was rated "Buy" at B. Riley Financial with an $11.00 price target [1]. Ovintiv (OVV) was rated "Buy" at Barclays Capital with a price target of $55.00 [1]. Phibro Animal Health (PAHC) was upgraded at JPMorgan Chase from Neutral to Overweight, with the price target raised from $25.00 to $35.00 [1]. Progressive (PGR) was downgraded by Morgan Stanley from Overweight to Equal Weight, with a price target of $290.00 [1]. Pulse Biosciences (PLSE) was initiated by Oppenheimer with an "Outperform" rating and a $22.00 price target [1]. PTC (PTC) had its Overweight rating reiterated by KeyCorp Bank [1]. Rockwell Automation (ROK) was initiated by CICC Research with a "Buy" rating and a price target of $320.00 [1].
[1] https://www.ainvest.com/news/business-15min-chart-triggers-bollinger-bands-narrowing-bearish-marubozu-pattern-2508/
[2] https://www.ainvest.com/news/trico-bancshares-9-1-dividend-hike-testament-financial-resilience-shareholder-commitment-2508/
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue

Comments
No comments yet